1
|
Culton D, Ujiie H, Schmidt E, Murrell D, Stoykov I, Verheesen P, Borradori L, Hall R, Joly P. 311 Treatment of bullous pemphigoid by inhibiting fcrn: Pre-registration report of a phase 2/3 trial with efgartigimod. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
So J, Fulchand S, Wong C, Li S, Nazaroff J, Gorell E, de Souza M, Murrell D, Teng J, Chiou A, Tang J. 194 Patient-reported disease burden in epidermolysis bullosa simplex (EBS). J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, Böckle BC, Caproni M, Caux F, Chandran NS, Cianchini G, Daneshpazhooh M, De D, Didona D, Di Zenzo GM, Dmochowski M, Drenovska K, Ehrchen J, Goebeler M, Groves R, Günther C, Horvath B, Hertl M, Hofmann S, Ioannides D, Itzlinger-Monshi B, Jedličková J, Kowalewski C, Kridin K, Lim YL, Marinovic B, Marzano AV, Mascaro JM, Meijer JM, Murrell D, Patsatsi K, Pincelli C, Prost C, Rappersberger K, Sárdy M, Setterfield J, Shahid M, Sprecher E, Tasanen K, Uzun S, Vassileva S, Vestergaard K, Vorobyev A, Vujic I, Wang G, Wozniak K, Yayli S, Zambruno G, Zillikens D, Schmidt E, Joly P. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36:1689-1704. [PMID: 35766904 DOI: 10.1111/jdv.18220] [Citation(s) in RCA: 50] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 05/04/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. OBJECTIVES AND METHODOLOGY The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. RESULTS Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. CONCLUSIONS The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
Collapse
Affiliation(s)
- L Borradori
- Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland
| | - N Van Beek
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - C Feliciani
- Dermatology Unit, Department of Medicine and Surgery, University Hospital, University of Parma, Italy
| | - B Tedbirt
- Department of Dermatology, Rouen University Hospital, Referral Center for Autoimmune Bullous Diseases, Referral Center for Autoimmune Bullous Diseases, Rouen University Hospital, INSERM U1234, Normandie University, Rouen, France
| | - E Antiga
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - R Bergman
- Department of Dermatology, Rambam Health Care Campus, Haifa, Israel.,Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - B C Böckle
- Department of Dermatology, Venereology & Allergology, Innsbruck Medical University, Innsbruck, Austria
| | - M Caproni
- Department of Health Sciences, Section of Dermatology, AUSL Toscana Centro, Rare Diseases Unit, European Reference Network-Skin Member, University of Florence, Italy
| | - F Caux
- Department of Dermatology and Referral Center for Autoimmune Bullous Diseases, Groupe Hospitalier Paris Seine-Saint-Denis, AP-HP and University Paris 13, Bobigny, France
| | - N S Chandran
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - G Cianchini
- Department of Dermatology, Ospedale Classificato Cristo Re, Rome, Italy
| | - M Daneshpazhooh
- Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - D De
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - D Didona
- Department of Dermatology and Allergology, Philipps University, Marburg, Germany
| | - G M Di Zenzo
- Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy
| | - M Dmochowski
- Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
| | - K Drenovska
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - J Ehrchen
- Department of Dermatology, University of Münster, Münster, Germany
| | - M Goebeler
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - R Groves
- St. John's Institute of Dermatology, Viapath Analytics LLP, St. Thomas' Hospital, London, UK.,Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, UK
| | - C Günther
- Department of Dermatology, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany
| | - B Horvath
- Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - M Hertl
- Department of Dermatology and Allergology, Philipps University, Marburg, Germany
| | - S Hofmann
- Department of Dermatology, Allergy and Dermatosurgery, Helios University Hospital Wuppertal, University Witten, Herdecke, Germany
| | - D Ioannides
- 1st Department of Dermatology-Venereology, Hospital of Skin and Venereal Diseases, Aristotle University Medical School, Thessaloniki, Greece
| | - B Itzlinger-Monshi
- Department of Dermatology, Venereology and Allergy, Clinical Center Landstrasse, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria.,Medical Faculty, The Sigmund Freud Private University, Vienna, Austria
| | - J Jedličková
- Department of Dermatovenereology, Masaryk University, University Hospital St. Anna, Brno.,Department of Dermatovenereology, University Hospital Brno, Brno, Czech Republic
| | - C Kowalewski
- Department Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
| | - K Kridin
- National Skin Centre, Singapore, Singapore
| | - Y L Lim
- Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia
| | - B Marinovic
- Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - A V Marzano
- Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - J-M Mascaro
- Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - J M Meijer
- Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - D Murrell
- Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia
| | - K Patsatsi
- 2nd Department of Dermatology, Autoimmune Bullous Diseases Unit, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece
| | - C Pincelli
- DermoLab, Institute of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - C Prost
- Department of Dermatology and Referral Center for Autoimmune Bullous Diseases, Groupe Hospitalier Paris Seine-Saint-Denis, AP-HP and University Paris 13, Bobigny, France
| | - K Rappersberger
- Department of Dermatology, Venereology and Allergy, Clinical Center Landstrasse, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria.,Medical Faculty, The Sigmund Freud Private University, Vienna, Austria.,Abteilung Dermatologie, Venerologie und Allergologie, Lehrkrankenhaus der Medizinischen Universität Wien, Austria
| | - M Sárdy
- Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany.,Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
| | - J Setterfield
- Department of Oral Medicine, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Shahid
- Department of Dermatology, Medical University, Sofia, Bulgaria
| | - E Sprecher
- Division of Dermatology, Tel Aviv Sourasky Medical Center and Department of Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - K Tasanen
- Department of Dermatology, the PEDEGO Research Unit, University of Oulu and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
| | - S Uzun
- Department of Dermatology and Venereology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - S Vassileva
- Department of Dermatology, Medical University, Sofia, Bulgaria
| | - K Vestergaard
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
| | - A Vorobyev
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany
| | - I Vujic
- Department of Dermatology, Venereology and Allergy, Clinical Center Landstrasse, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria.,Medical Faculty, The Sigmund Freud Private University, Vienna, Austria
| | - G Wang
- Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
| | - K Wozniak
- National Skin Centre, Singapore, Singapore
| | - S Yayli
- Department of Dermatology, School of Medicine, Koç University, Istanbul, Turkey
| | - G Zambruno
- Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - D Zillikens
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany
| | - E Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany
| | - P Joly
- Department of Dermatology, Rouen University Hospital, Referral Center for Autoimmune Bullous Diseases, Referral Center for Autoimmune Bullous Diseases, Rouen University Hospital, INSERM U1234, Normandie University, Rouen, France
| |
Collapse
|
4
|
Schmidt E, Rashid H, Marzano A, Lamberts A, Di Zenzo G, Diercks G, Alberti‐Violetti S, Barry R, Borradori L, Caproni M, Carey B, Carrozzo M, Cianchini G, Corrà A, Dikkers F, Feliciani C, Geerling G, Genovese G, Hertl M, Joly P, Meijer J, Mercadante V, Murrell D, Ormond M, Pas H, Patsatsi A, Rauz S, van Rhijn B, Roth M, Setterfield J, Zillikens D, C.Prost, Zambruno G, Horváth B, Caux F. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol 2021; 35:1926-1948. [PMID: 34309078 PMCID: PMC8518905 DOI: 10.1111/jdv.17395] [Citation(s) in RCA: 71] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 03/24/2021] [Indexed: 01/21/2023]
Abstract
This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue-bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10-25% of patients laminin 332 is recognized. In 25-30% of MMP patients with anti-laminin 332 reactivity, malignancies have been associated. As first-line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first-line regimens. Additional recommendations are given, tailored to treatment of single-site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high-quality randomized controlled trials.
Collapse
|
5
|
Rashid H, Lamberts A, Borradori L, Alberti‐Violetti S, Barry R, Caproni M, Carey B, Carrozzo M, Caux F, Cianchini G, Corrà A, Diercks G, Dikkers F, Di Zenzo G, Feliciani C, Geerling G, Genovese G, Hertl M, Joly P, Marzano A, Meijer J, Mercadante V, Murrell D, Ormond M, Pas H, Patsatsi A, Prost C, Rauz S, van Rhijn B, Roth M, Schmidt E, Setterfield J, Zambruno G, Zillikens D, Horváth B. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol 2021; 35:1750-1764. [PMID: 34245180 PMCID: PMC8457055 DOI: 10.1111/jdv.17397] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 05/17/2021] [Indexed: 12/15/2022]
Abstract
This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline encompassing a systematic review of the literature until June 2019 in the MEDLINE and EMBASE databases. This first part covers methodology, the clinical definition of MMP, epidemiology, MMP subtypes, immunopathological characteristics, disease assessment and outcome scores. MMP describes a group of autoimmune skin and mucous membrane blistering diseases, characterized by a chronic course and by predominant involvement of the mucous membranes, such as the oral, ocular, nasal, nasopharyngeal, anogenital, laryngeal and oesophageal mucosa. MMP patients may present with mono- or multisite involvement. Patients' autoantibodies have been shown to be predominantly directed against BP180 (also called BPAG2, type XVII collagen), BP230, laminin 332 and type VII collagen, components of junctional adhesion complexes promoting epithelial stromal attachment in stratified epithelia. Various disease assessment scores are available, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI), the Autoimmune Bullous Skin disorder Intensity Score (ABSIS), the 'Cicatrising Conjunctivitis Assessment Tool' and the Oral Disease Severity Score (ODSS). Patient-reported outcome measurements (PROMs), including DLQI, ABQOL and TABQOL, can be used for assessment of quality of life to evaluate the effectiveness of therapeutic interventions and monitor disease course.
Collapse
|
6
|
Bruckner A, Kern J, Sprecher E, Fernandez M, Cunningham T, Sumeray M, Murrell D. 615 Efficacy and safety of Oleogel-S10 (birch triterpenes) for recessive dystrophic epidermolysis bullosa (RDEB): Results of 3 months double-blind treatment of the phase 3 study ‘EASE’. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Liang Y, Sheriff T, Bilgic A, Stone J, Feng G, Murrell D. 415 Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease (AIBD) using the Glucocorticoid Toxicity Index (GTI). J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Wilson B, Sun M, Olayinka J, Murrell D, Murase J. 557 Assessment of skin of color and diversity and inclusion content published in the Journal of Investigative Dermatology: An analysis and call to action. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Silverberg J, Pinter A, Alavi A, Lynde C, Bouaziz J, Wollenberg A, Murrell D, Alpizar S, Laquer V, Chaouche K, Ahmad F, Armstrong J, Piketty C. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study. J Eur Acad Dermatol Venereol 2021; 35:1562-1568. [DOI: 10.1111/jdv.17218] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 02/18/2021] [Indexed: 02/05/2023]
Affiliation(s)
- J.I. Silverberg
- Department of Dermatology The George Washington University School of Medicine and Health Sciences Washington DC USA
| | - A. Pinter
- Department of Dermatology, Venereology, and Allergology University Hospital Frankfurt am Main Frankfurt am Main Germany
| | - A. Alavi
- Department of Dermatology Mayo Clinic Rochester MN USA
| | - C. Lynde
- Department of Medicine University of Toronto Toronto ON Canada
| | - J.‐D. Bouaziz
- Department of Dermatology Paris VII Sorbonne Paris Cité University Assistance Publique – Hôpitaux de Paris Paris France
| | - A. Wollenberg
- Department of Dermatology and Allergology Ludwig‐Maximilians‐Universität Munich Germany
| | - D.F. Murrell
- Department of Dermatology St George Clinical SchoolUniversity of New South Wales Sydney NSW Australia
| | - S. Alpizar
- Clinical Research Trials of Florida Tampa FL USA
| | - V. Laquer
- First OC Dermatology Fountain Valley CA USA
| | | | - F. Ahmad
- Galderma Laboratories Fort Worth TX USA
| | | | | |
Collapse
|
10
|
Kang M, Bilgic A, Radjenovic M, Murrell D. Osteoporosis and bone health in autoimmune blistering skin disease—an evidenced based review. J Eur Acad Dermatol Venereol 2020; 34:2745-2756. [DOI: 10.1111/jdv.16334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 02/12/2020] [Indexed: 11/30/2022]
Affiliation(s)
- M. Kang
- Faculty of Medicine University of New South Wales Sydney NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
| | - A. Bilgic
- Faculty of Medicine University of New South Wales Sydney NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
- Dermatology Clinic Seydisehir State Hospital Seydisehir, Konya Turkey
| | - M. Radjenovic
- Faculty of Medicine University of New South Wales Sydney NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
| | - D.F. Murrell
- Faculty of Medicine University of New South Wales Sydney NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
| |
Collapse
|
11
|
Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, Bergman R, Bernard P, Borradori L, Caproni M, Caux F, Cianchini G, Daneshpazhooh M, De D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Guenther C, Hofmann S, Ioannides D, Kowalewski C, Ludwig R, Lim Y, Marinovic B, Marzano A, Mascaró J, Mimouni D, Murrell D, Pincelli C, Squarcioni C, Sárdy M, Setterfield J, Sprecher E, Vassileva S, Wozniak K, Yayli S, Zambruno G, Zillikens D, Hertl M, Schmidt E. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34:1900-1913. [DOI: 10.1111/jdv.16752] [Citation(s) in RCA: 88] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 05/29/2020] [Indexed: 01/21/2023]
|
12
|
Ferries L, Gillibert A, Duvert‐Lehembre S, Corbaux C, Alexandre M, Prost‐Squarcioni C, Caux F, Delaporte E, Litrowski N, Boulard C, Murrell D, Joly P, Hébert V. Sensitivity to change and correlation between the autoimmune bullous disease quality‐of‐life questionnaires
ABQOL
and
TABQOL
, and objective severity scores. Br J Dermatol 2020; 183:944-945. [DOI: 10.1111/bjd.19173] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L. Ferries
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - A. Gillibert
- Department of Biostatistics Rouen University Hospital and INSERM U1219 Normandie University Rouen France
| | - S. Duvert‐Lehembre
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - C. Corbaux
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - M. Alexandre
- Department of Dermatology University of Paris XIII Bobigny France
| | | | - F. Caux
- Department of Dermatology University of Paris XIII Bobigny France
| | - E. Delaporte
- Department of Dermatology Claude Huriez University Hospital University of Lille Lille France
| | - N. Litrowski
- Department of Dermatology Jacques Monod Le Havre University Hospital Montivilliers France
| | - C. Boulard
- Department of Dermatology Jacques Monod Le Havre University Hospital Montivilliers France
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of New South Wales Sydney NSW Australia
| | - P. Joly
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - V. Hébert
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| |
Collapse
|
13
|
Guignant M, Murrell D, Schimdt E, Zillikens D, Prost C, Caux F, Joly P. Comment les experts internationaux traitent-ils les patients atteints de pemphigoïde bulleuse à travers le monde ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Yang A, Xuan R, Melbourne W, Hashimoto T, Uzun S, Daneshpazhooh M, Yamagami J, Di Zenzo G, Mascaro J, Mahmoudi H, Patsatsi A, Drenovska K, Vassileva S, Murrell D. Inter‐rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. J Eur Acad Dermatol Venereol 2019; 33:2327-2333. [DOI: 10.1111/jdv.15817] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2019] [Accepted: 07/03/2019] [Indexed: 01/10/2023]
Affiliation(s)
- A. Yang
- University of New South Wales Kogarah NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
| | - R.R. Xuan
- University of New South Wales Kogarah NSW Australia
| | - W. Melbourne
- Department of Dermatology St George Hospital Sydney NSW Australia
| | - T. Hashimoto
- Department of Dermatology Osaka City University Graduate School of Medicine Osaka Japan
| | - S. Uzun
- Department of Dermatology Akdeniz University School of Medicine Antalya Turkey
| | - M. Daneshpazhooh
- Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran
| | - J. Yamagami
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - G. Di Zenzo
- Molecular and Cell Biology laboratory IDI‐IRCCS Rome Italy
| | - J.M. Mascaro
- Hospital Clinic and Barcelona University Medical School Barcelona Spain
| | - H. Mahmoudi
- Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran
| | - A. Patsatsi
- 2nd Dermatology Department Aristotle University School of Medicine Thessaloniki Greece
| | - K. Drenovska
- Department of Dermatology and Venereology Sofia University of Medicine Sofia Bulgari
| | - S. Vassileva
- Department of Dermatology and Venereology Sofia University of Medicine Sofia Bulgari
| | - D.F. Murrell
- University of New South Wales Kogarah NSW Australia
- Department of Dermatology St George Hospital Sydney NSW Australia
| |
Collapse
|
15
|
Daniel B, Murrell D. Review of autoimmune blistering diseases: the Pemphigoid diseases. J Eur Acad Dermatol Venereol 2019; 33:1685-1694. [DOI: 10.1111/jdv.15679] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Accepted: 05/03/2019] [Indexed: 12/30/2022]
Affiliation(s)
- B.S. Daniel
- St Vincent's Hospital Melbourne Australia
- St George Hospital Sydney Australia
- University of New South Wales Sydney Australia
| | - D.F. Murrell
- St George Hospital Sydney Australia
- University of New South Wales Sydney Australia
| |
Collapse
|
16
|
Murrell D, Stavropoulos P, Patsatsi A, Zeeli T, Baum S, Bassukas I, Caux F, Roussaki A, Sinclair R, Kern J, Gourlay S, Joly P. LB1509 Anti-desmoglein levels & response to the BTK inhibitor PRN1008 in pemphigus. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Xuan R, Yang A, Melbourne W, Hashimoto T, Uzun S, Daneshpazhooh M, Yamagami J, Di Zenzo G, Mascaro J, Murrell D. 059 Reliability of the BIOCHIP in pemphigus and pemphigoid patients the evaluations of blistering disease experts. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Drucker A, Eyerich K, de Bruin-Weller M, Thyssen J, Spuls P, Irvine A, Girolomoni G, Dhar S, Flohr C, Murrell D, Paller A, Guttman-Yassky E. 对过敏性皮肤炎使用全身用糖皮质激素:国际湿疹理事会共识声明. Br J Dermatol 2018. [DOI: 10.1111/bjd.16452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Drucker A, Eyerich K, de Bruin-Weller M, Thyssen J, Spuls P, Irvine A, Girolomoni G, Dhar S, Flohr C, Murrell D, Paller A, Guttman-Yassky E. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018. [DOI: 10.1111/bjd.16385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Murrell D. [New developments in the management of congenital epidermolysis bullosa]. Ann Dermatol Venereol 2017; 144:S6-S7. [PMID: 29096942 DOI: 10.1016/j.annder.2017.09.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- D Murrell
- Service de dermatologie, hôpital St-George, université de Nouvelle-Galles-du-Sud, Sydney, Australie.
| |
Collapse
|
21
|
Harris A, Murrell D. 034 Surgical wound healing in patients with epidermolysis bullosa. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Lee B, Radjenovic M, Tan J, Coroneo M, Murrell D. 066 Methods for grading severity of ocular involvement in patients with mucous membrane pemphigoid. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Guttman-Yassky E, Yosipovitch G, Murrell D, Hanifin J. 012 Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Affiliation(s)
- A. Patsatsi
- 2nd Department of Dermatology; Aristotle University Faculty of Medicine; Papageorgiou General Hospital; Ring Road, 56403 N. Efkarpia Thessaloniki Greece
| | - D.F. Murrell
- Department of Dermatology; St George Hospital; University of New South Wales; Sydney NSW Australia
| |
Collapse
|
25
|
Gollins C, Shipman A, Murrell D. A study of the number of female editors-in-chief of dermatology journals. Int J Womens Dermatol 2017; 3:185-188. [PMID: 29234711 PMCID: PMC5715225 DOI: 10.1016/j.ijwd.2017.03.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 02/28/2017] [Accepted: 03/06/2017] [Indexed: 11/29/2022] Open
Abstract
Introduction Over the past 50 years the proportion of women entering medical school has vastly increased, however there still exists a gender gap in top leadership positions, including within academic medicine. It is important to investigate the influence of women in this area, and assess change over time. The aim of the study was to assess the number of women who have acted as editors-in-chief of prominent dermatology journals over the 20th and 21st centuries. Methods A list of 25 journals was collated based on their impact factors and prominence. Information regarding previous and current editors was obtained, compiled and analysed. Results Overall there have been 26 female editors and at least 128 male editors in the 25 dermatology journals, which means that less than 19% of editors-in-chief have been female. 45.8% of journals have not yet had a female editor. The percentage of female editors ranged from 0% to 100%, with only one journal having had all female editors (International Journal of Women’s Dermatology). On average, the journals had female editorship for 27.2% of the total number of years in publication. Of the 13 journals that have had a female editor, 61.5% had their first female editor after the year 2000. Discussion and Conclusion There are various factors that influence these numbers including age of the journals and length of each editorship. It is clear that over time there has been an increase in the number of women holding these prestigious positions however gender equity has not yet been reached.
Collapse
Affiliation(s)
- C.E. Gollins
- Department of Dermatology, St George Hospital, Sydney, Australia
| | - A.R. Shipman
- Department of Dermatology, St Mary's NHS Treatment Centre, Portsmouth, United Kingdom
| | - D.F. Murrell
- Department of Dermatology, St George Hospital, Sydney, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
- Corresponding Author.
| |
Collapse
|
26
|
Zhao C, Hao E, Oh D, Daniel B, Martin L, Su J, Rodrigues M, Murrell D. A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. Br J Dermatol 2017; 176:985-992. [DOI: 10.1111/bjd.15271] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/21/2016] [Indexed: 01/28/2023]
Affiliation(s)
- C.Y. Zhao
- St George Hospital; Sydney Australia
- University of New South Wales; Sydney Australia
| | - E.Y. Hao
- University of New South Wales; Sydney Australia
| | - D.D. Oh
- University of New South Wales; Sydney Australia
| | - B.S. Daniel
- University of New South Wales; Sydney Australia
- St Vincent's Hospital; Melbourne Australia
| | - L.K. Martin
- University of New South Wales; Sydney Australia
- Sydney Children's Hospital; Sydney Australia
| | - J.C. Su
- Royal Children's Hospital; Melbourne Australia
- Monash University; Eastern Health; Box Hill Australia
| | - M. Rodrigues
- St Vincent's Hospital; Melbourne Australia
- Royal Children's Hospital; Melbourne Australia
| | - D.F. Murrell
- St George Hospital; Sydney Australia
- University of New South Wales; Sydney Australia
| |
Collapse
|
27
|
Murrell D. Why have hospitalization rates for bullous pemphigoid soared? Br J Dermatol 2017; 176:5-6. [DOI: 10.1111/bjd.15190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- D.F. Murrell
- Department of Dermatology St George Hospital University of New South Wales, Faculty of Medicine Gray St, Kogarah Sydney NSW 2217 Australia
| |
Collapse
|
28
|
Chalmers J, Simpson E, Apfelbacher C, Thomas K, Kobyletzki L, Schmitt J, Singh J, Svensson Å, Williams H, Abuabara K, Aoki V, Ardeleanu M, Awici‐Rasmussen M, Barbarot S, Berents T, Block J, Bragg A, Burton T, Bjerring Clemmensen K, Creswell‐Melville A, Dinesen M, Drucker A, Eckert L, Flohr C, Garg M, Gerbens L, Graff A, Hanifin J, Heinl D, Humphreys R, Ishii H, Kataoka Y, Leshem Y, Marquort B, Massuel M, Merhand S, Mizutani H, Murota H, Murrell D, Nakahara T, Nasr I, Nograles K, Ohya Y, Osterloh I, Pander J, Prinsen C, Purkins L, Ridd M, Sach T, Schuttelaar MA, Shindo S, Smirnova J, Sulzer A, Synnøve Gjerde E, Takaoka R, Vestby Talmo H, Tauber M, Torchet F, Volke A, Wahlgren C, Weidinger S, Weisshaar E, Wollenberg A, Yamaga K, Zhao C, Spuls P. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016; 175:69-79. [DOI: 10.1111/bjd.14773] [Citation(s) in RCA: 98] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2016] [Indexed: 12/24/2022]
|
29
|
Affiliation(s)
- A.G. Harris
- Department of Dermatology; St George Hospital; Sydney NSW Australia
- Faculty of Medicine; University of New South Wales; Sydney NSW Australia
| | - C. Choy
- The Skin and Cancer Foundation; Sydney NSW Australia
| | - M. Pigors
- Centre for Cutaneous Research; Blizard Institute, Barts and The London School of Medicine and Dentistry; Queen Mary University of London; London U.K
| | - D.P. Kelsell
- Centre for Cutaneous Research; Blizard Institute, Barts and The London School of Medicine and Dentistry; Queen Mary University of London; London U.K
| | - D.F. Murrell
- Department of Dermatology; St George Hospital; Sydney NSW Australia
- Faculty of Medicine; University of New South Wales; Sydney NSW Australia
| |
Collapse
|
30
|
Kim M, Li M, Intong L, Murrell D. 136 Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa in Australasia: 1991-2015. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Chao L, Gor V, Murrell D, Kim M, O’Toole E, Ly A, Woodley D, Wysong A, Chen M. 421 Over-expression of periostin is associated with clinical outcomes and poor prognosis in cutaneous squamous cell carcinoma. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
Affiliation(s)
- C. Boulard
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - S. Duvert Lehembre
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - C. Picard‐Dahan
- Department of Dermatology Bichat University Hospital AP‐HP Paris France
| | - J.S. Kern
- Department of Dermatology Medical Center University of Freiburg Freiburg Germany
| | - G. Zambruno
- Laboratory of Molecular and Cell Biology Istituto Dermopatico dell'Immacolata IRCCS Via Monti di Creta 104 00167 Roma Italy
| | - C. Feliciani
- Policlinico Gemelli – Università Cattolica del ‘Sacro Cuore’ Largo Gemelli 8 00168 Roma Italy
| | - B. Marinovic
- University Hospital Center Zagreb Department of Dermatology and Venereology Salata 4 10000 Zagreb Croatia
| | - P. Vabres
- Department of Dermatology Dijon University Hospital Dijon France
| | - L. Borradori
- Department of Dermatology Universitätsklinik für Dermatologie Inselspital CH‐3010 Bern Switzerland
| | - C. Prost‐Squarcioni
- Department of Dermatology Avicenne Hospital University Paris 13 Bobigny France
| | - B. Labeille
- Department of Dermatology Saint Etienne University Hospital Saint Etienne France
| | - M.A. Richard
- Aix‐Marseille University UMR 911 INSERM CRO2 ‘Centre de Recherche en Oncologie Biologique et Oncophamacologie’ Department of Dermatology Hôpital Timone Assistance Publique des Hôpitaux de Marseille 264 Rue Saint Pierre 13385 Marseille France
| | - S. Ingen‐Housz‐Oro
- Department of Dermatology Henri Mondor University Hospital AP‐HP Créteil France
| | - E. Houivet
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - V.P. Werth
- Department of Dermatology University of Pennsylvania, and Philadelphia VAMC Philadelphia PA U.S.A
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney Australia
| | - M. Hertl
- Department of Dermatology Philipps University Marburg Marburg Germany
| | - J. Benichou
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Oh D, Zhao C, Murrell D. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. J Eur Acad Dermatol Venereol 2015; 30:595-603. [DOI: 10.1111/jdv.13386] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 08/07/2015] [Indexed: 01/21/2023]
Affiliation(s)
- D.D. Oh
- Department of Dermatology; St George Hospital; Sydney NSW Australia
- University of New South Wales; Sydney NSW Australia
| | - C.Y. Zhao
- Department of Dermatology; St George Hospital; Sydney NSW Australia
- University of New South Wales; Sydney NSW Australia
| | - D.F. Murrell
- Department of Dermatology; St George Hospital; Sydney NSW Australia
- University of New South Wales; Sydney NSW Australia
| |
Collapse
|
36
|
Zhao C, Frew J, Muhaidat J, Cheung K, Lee P, Poulos V, McCrossin I, Cachia A, Tefany F, Murrell D. Chlorophyll‐induced pseudoporphyria with ongoing photosensitivity after cessation – a case series of four patients. J Eur Acad Dermatol Venereol 2015; 30:1239-42. [DOI: 10.1111/jdv.13169] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C.Y. Zhao
- Dermatology St George Hospital Sydney Australia
- Medicine University of New South Wales Sydney Australia
| | - J.W. Frew
- Medicine University of New South Wales Sydney Australia
- Dermatology St Vincent's Hospital Sydney Australia
| | - J. Muhaidat
- Pathology Skin and Cancer Foundation Sydney Australia
| | - K. Cheung
- Pathology Skin and Cancer Foundation Sydney Australia
| | - P. Lee
- Eastern Suburbs Dermatology Sydney Australia
| | - V. Poulos
- Biochemistry Royal Prince Alfred Hospital Sydney Australia
| | | | - A.R. Cachia
- Dermatology St Vincent's Hospital Sydney Australia
| | - F. Tefany
- Dermatology St Vincent's Hospital Sydney Australia
- Southern Highlands Dermatology Bowral Australia
| | - D.F. Murrell
- Dermatology St George Hospital Sydney Australia
- Medicine University of New South Wales Sydney Australia
| |
Collapse
|
37
|
Rubel D, Spelman L, Murrell D, See J, Hewitt D, Foley P, Bosc C, Kerob D, Kerrouche N, Wulf H, Shumack S. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014; 171:1164-71. [DOI: 10.1111/bjd.13138] [Citation(s) in RCA: 160] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2014] [Indexed: 11/28/2022]
Affiliation(s)
- D.M. Rubel
- Woden Dermatology and Probity Medical Research Level 1, 1 Bowes Place Phillip ACT 2606 Australia
- Australian National University Canberra Australia
| | - L. Spelman
- Specialist Connect Woolloongabba Qld Australia
| | - D.F. Murrell
- Premier Specialists Kogarah Sydney NSW Australia
- University of NSW Sydney NSW Australia
| | - J.‐A. See
- Central Sydney Dermatology Sydney NSW Australia
| | - D. Hewitt
- Skin and Cancer Foundation Westmead NSW Australia
| | - P. Foley
- Skin and Cancer Foundation Inc. Carlton Vic. Australia
- The University of Melbourne Parkville Vic. Australia
- St Vincent's Hospital Fitzroy Melbourne Vic. Australia
| | - C. Bosc
- Galderma R&D Sophia Antipolis France
| | - D. Kerob
- Galderma International Paris France
| | | | - H.C. Wulf
- Bispebjerg Hospital Copenhagen University Copenhagen Denmark
| | - S. Shumack
- St George Dermatology and Skin Cancer Centre and Probity Medical Research Kogarah Sydney NSW Australia
| |
Collapse
|
38
|
Boulard C, Bouyeure A, Houivet E, Borradori L, Huenefeld C, Schmidt E, Marinovic B, Zambruno G, Feliciani C, Prost C, Picard-Dahan C, Duvert Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Caux F, Bouaziz J, Oro S, Avenel-Audran M, Misery L, Sassolas B, Alexandre M, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabre P, Dereure O, Skowron F, Franck N, Beylot-Barry M, Beneton Benhard N, Debarbieux S, Jullien D, Benichou J, Ferranti V, Murrell D, Hertl M, Joly P. Qualité de vie chez les patients atteints de pemphigus : corrélation avec le type et la sévérité du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Sekulic A, Migden M, Seguin NB, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell D, Omid H, Quevedo J, Hou J, Yue H, Schadendorf D. Efficacité et tolérance à long terme du vismodegib chez des patients présentant un carcinome basocellulaire avancé (CBCa) : mise à jour à 18 mois de l’étude pivot ERIVANCE CBC. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Murrell D. Book Review: Fluids and Electrolytes in Pediatrics. Anaesth Intensive Care 2013. [DOI: 10.1177/0310057x1304100125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Van Geel M, Gattas M, Kesler Y, Tong P, Yan H, Tran K, Steijlen P, Murrell D, Van Steensel M. Phenotypic variability associated with WNT10A
nonsense mutations. Br J Dermatol 2010; 162:1403-6. [DOI: 10.1111/j.1365-2133.2010.09703.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Frew J, Martin L, Nijsten T, Murrell D. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol 2009; 161:1323-30. [DOI: 10.1111/j.1365-2133.2009.09347.x] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Murrell D. Book Review: Anesthesia for Genetic, Metabolic, and Dysmorphic Syndromes of Childhood. Anaesth Intensive Care 2008. [DOI: 10.1177/0310057x0803600630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Murrell D, Calvieri S, Ortonne J, Ho V, Weise-Riccardi S, Barbier N, Paul C. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007; 157:954-9. [DOI: 10.1111/j.1365-2133.2007.08192.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
45
|
Boyle RJ, Bath-Hextall F, Donath S, Murrell D, Tang MLK, Taylor J, Varigos G. Probiotics for atopic eczema. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2006. [DOI: 10.1002/14651858.cd006135] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
46
|
Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Paller A, de Prost Y, Puig L, Ring J, Saurat JH, Schwarz T, Shear N, Stingl G, Taieb A, Thestrup-Pedersen K. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211:77-8. [PMID: 16088148 DOI: 10.1159/000086431] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
47
|
Abstract
BACKGROUND Bullous pemphigoid is the most common autoimmune bullous disease in the West. Oral steroids are considered the standard treatment. OBJECTIVES To assess the effects of treatments for bullous pemphigoid. SEARCH STRATEGY We searched the Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE to March 2003 and bibliographies from identified studies. SELECTION CRITERIA Randomised controlled trials of treatments for patients with immunofluorescence confirmed bullous pemphigoid. DATA COLLECTION AND ANALYSIS Two reviewers evaluated the studies in terms of the inclusion criteria, five extracted data independently; disagreements were resolved by discussion. Statistical pooling of the data was inappropriate because of heterogeneity of treatments. MAIN RESULTS We found seven randomised controlled trials with a total of 634 patients. All studies involved different comparisons, none included a placebo group. Different doses, different formulations of corticosteroids and the addition of azathioprine failed to show significant differences in measures of disease control. However, patients who took azathioprine were able to almost halve the amount of prednisone required for disease control. Plasma exchange plus prednisone achieved significantly better disease control than prednisone alone; this favourable effect was not apparent in another study. The latter study also compared plasma exchange or azathioprine plus prednisone, but failed to show significant differences for disease control or mortality, although total adverse events at six months almost reached statistical significance in favour of plasma exchange plus prednisone. Comparing tetracycline plus nicotinamide with prednisolone, no significant difference for disease response was shown. A very potent topical corticosteroid was compared to oral prednisone in patients with moderate and extensive disease. In patients with extensive disease, the topical steroid group showed significantly better survival and disease control, and less severe complications, while no significant differences for these outcomes were seen in patients with moderate disease. Most of the reported deaths were in patients taking high doses of oral corticosteroids. AUTHORS' CONCLUSIONS Very potent topical steroids are effective and safe treatments for bullous pemphigoid; their use in extensive disease may be limited by side effects and practical factors. Starting doses of prednisolone greater than 0.75 mg/kg/day do not seem to give additional benefit, lower doses may be adequate for disease control; this could reduce the incidence and severity of adverse reactions. The effectiveness of the addition of plasma exchange or azathioprine to corticosteroids has not been established. Combination treatment with tetracycline and nicotinamide may be useful; this needs further validation.
Collapse
Affiliation(s)
- N Khumalo
- Dermatology Department, Groote Schuur Hospital, Cape Town, Anzio Road, Observatory, Cape Town, Western Cape, South Africa, 7925.
| | | | | | | | | | | |
Collapse
|
48
|
Murrell D. Book Review: Pediatric Anesthesia—The Requisites in Anes-thesiology. Anaesth Intensive Care 2005. [DOI: 10.1177/0310057x0503300325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- D. Murrell
- Westmead Children's Hospital, Sydney, New South Wales
| |
Collapse
|
49
|
Vinciullo C, Elliott T, Francis D, Gebauer K, Spelman L, Nguyen R, Weightman W, Sheridan A, Reid C, Czarnecki D, Murrell D. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152:765-72. [PMID: 15840111 DOI: 10.1111/j.1365-2133.2005.06484.x] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Basal cell carcinoma (BCC) may be difficult to treat by conventional means, particularly if the lesions are large or located in the mid-face (H-zone). Photodynamic therapy (PDT) using topical methyl aminolaevulinate (MAL) may be a good noninvasive option for these patients. OBJECTIVES To investigate the efficacy and safety of PDT using MAL for BCCs defined as 'difficult to treat', i.e. large lesions, in the H-zone, or in patients at high risk of surgical complications. METHODS This was a prospective, multicentre, noncomparative study. Patients were assessed 3, 12 and 24 months after the last PDT treatment. One hundred and two patients with 'difficult-to-treat' BCC were treated with MAL PDT, using 160 mg g(-1) cream and 75 J cm(-2) red light (570-670 nm), after lesion preparation and 3 h of cream exposure. Results Ninety-five patients with 148 lesions were included in the per protocol analysis. The histologically confirmed lesion complete response rate at 3 months was 89% (131 of 148). At 12 months, 10 lesions had reappeared, and therefore the cumulative treatment failure rate was 18% (27 of 148). At 24 months, an additional nine lesions had reappeared, resulting in a cumulative treatment failure rate of 24% (36 of 148). The estimated sustained lesion complete response rate (assessed using a time-to-event approach) was 90% at 3 months, 84% at 12 months and 78% at 24 months. Overall cosmetic outcome was judged as excellent or good in 79% and 84% of the patients at 12 and 24 months, respectively. Follow-up is continuing for up to 5 years. CONCLUSIONS MAL PDT is an attractive option for 'difficult-to-treat' BCC. Because of the excellent cosmetic results, the treatment is particularly well suited for lesions that would otherwise require extensive surgical procedures.
Collapse
Affiliation(s)
- C Vinciullo
- Fremantle Hospital, Fremantle, Western Australia, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
The primary aim of this study was to prospectively investigate whether there was an association between the duration of post-operative catheterisation and the incidence of bladder spasm in children following ureteric reimplantation surgery. A secondary aim was to investigate whether other surgical and post-operative factors had an effect on the incidence of bladder spasm.
Collapse
Affiliation(s)
- D Gillies
- School of Nursing, Family and Community Health, University of Western Sydney, Locked Bag 1797, NSW 1797, Penrith South DC, Australia.
| | | | | | | |
Collapse
|